23 closest matches · ranked by relevance
Cowden's Disease · Hamartoma Syndrome, Multiple
Primary: Biochemical Changes in Benign and Malignant Tumor Tissues as Assessed by Immunohistochemistry.
Progressive Desmoids Tumors
Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…
Basal Cell Nevus Syndrome
Primary: Number of New BCCs Per Participant — 2.84; 4.03 New basal cell carcinomas
Von Hippel-Lindau Disease
Primary: Number of Patients With Pancreatic Lesions Defined by Simple Cysts, Microcystic Adenomas, Neuroendocrine Tumors & Other Solid Lesions of the Pancreas Who Had Significant…
PTEN Gene Mutation · PTEN Hamartoma Tumor Syndrome
Primary: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], Dropout — 3; 2; 5; 2 Participants
BRAF V600E Mutation
Primary: Number of Participants With Partial Response to Dabrafenib and Trametinib — 4 Participants
Medullary Thyroid Carcinoma · Multiple Endocrine Neoplasia Type 2A · Multiple Endocrine Neoplasia Type 2B
Primary: Maximum Tolerated Dose (MTD) — 100 mg/m^2/day
Rothmund-Thomson Syndrome
Primary: Bone Density (Low Areal Bone Mineral Density (aBMD)) — -1.3; -0.9; -2.4; -1.2 z-score
Dermatofibrosarcoma Protuberans
Primary: To Collect Matched Tumor Tissue of Trial Participants With Dermatofibrosarcoma Protuberans Before and After Treatment With Imatinib for Future Use in cDNA Microarray and…
Gastric Cancer · Gastric Neoplasms · Gastric Adenocarcinoma
Primary: Proportion of Participants With Improved Sensitivity for Detection of Early-stage Gastric Cancer in CDH1 Germline Mutation Carriers Compared to the Cambridge Method — 1…
Desmoid Tumor
Primary: Immunohistochemical Immunoreactive Score Results After 4 Weeks of Sirolimus Compared to Control Specimens — 5.22; 7.44; 4.47; 9.39 score on a scale — p=0.63
Thyroid Cancer
Primary: Objective Response Rate — 6 Participants
Thyroid Cancer
Primary: Objective Response Rate (ORR) — 3 Participants
Dent Disease
Primary: Change in Urine Total Protein — 1681; 59 mg/day
Pseudohypoparathyroidism · Albright Hereditary Osteodystrophy
Primary: Intelligence Quotient — 85.9; 104.3; 103.2 units on a scale
BCC - Basal Cell Carcinoma · BCC · Excision Margin
Primary: Number of Lesions With BCC Histological Clearance — 34 BCC Lesions
PIK3CA-Related Overgrowth Spectrum (PROS) · Growth Disorder · Genetics
Primary: Percent Change in Unaffected and Affected Fibrofatty Tissue Measured by DXA — 7.9; 4.8; 0.71; 6.5 mean percentage change in tissue volume
Desmoid Fibromatosis
Primary: Progression-free Survival(PFS) Rate — 7; 22; 42; 13 Participants — p=<0.001
Acromegaly
Primary: Effect of Pegvisomant on Colon Tissue p53 Expression — 330.57 ng/mL
Desmoid Tumors · Aggressive Fibromatosis
Primary: Number of Participants With a Complete Response (CR) + Partial Response (PR) — 0; 5; 1; 11 Participants
Giant Cell Tumors
Primary: Number of Participants According to the Management Plan in Patients With Diffuse TGCT (d-TGCT) — 94; NA; NA; NA Participants
Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients
Primary: Percentage of BCCs With Complete and at Least Partial Clinical Clearance — 92; 7; 83; 77 Percentage of BCCs
Basal Cell Nevus Syndrome
Primary: Clinical Efficacy: Percent Change in Tumor Size of Treatment-targeted Surgically Eligible Basal Cell Carcinomas (SEBs) From Baseline — 51.29; 26.63; 21.82 percentage…